search
Back to results

Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2

Primary Purpose

Cocaine-Related Disorders

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Propranolol
Amantadine
Placebo
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring cocaine

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male and females, 18 to 60 years old. Meets DSM-IV diagnosis criteria for cocaine dependence as determined by the Structured Clinical Interview for DSM-IV (SCID) Score of at least (> or =) 22 on the Initial Cocaine Selective Severity Assessment (CSSA) Lives within commuting distance of the Treatment Research Center (TRC) and the Penn/VA Center for Studies of Addiction, University of Pennsylvania If female, willing to use contraception throughout the study Continued use of cocaine during a two week evaluation phase prior to medication treatment as demonstrated by at least 2 new uses of cocaine documented by quantitative urine toxicology screen obtained three times weekly according to new use rules Exclusion Criteria: Meets DSM-IV/SCID diagnosis criteria for dependence on any drugs other than cocaine, marijuana, or nicotine. Cocaine dependent subjects who identify cocaine dependence as their primary addiction but who also meet criteria for alcohol dependence will be accepted as long as the alcohol dependence is not severe enough to require medications for alcohol detoxification. Concomitant treatment with psychotropic medications. Patients mandated to treatment based upon a legal decision or as a condition of employment. This will be assessed by the patient's self-report. Current severe psychiatric symptoms (e.g., psychosis, dementia, suicidal or homicidal ideation, mania or depression requiring antidepressant medication) Sensitivity to propranolol or amantadine Use of any investigational medication within the past 30 days. History of significant heart disease (an arrhythmia which required medication, Wolff-Parkinson -White Syndrome, angina pectoris, documented history of myocardial infarction, heart failure). History of chest pain associated with cocaine use which has prompted a visit to a physician. Current use of reserpine, verapamil, theophylline, trimethoprim, cimetidine, haloperidol, benzodiazepines, or anticonvulsants Bronchospastic disease Hyperthyroidism Diabetes mellitus Patients with known AIDS or other serious illnesses which may require hospitalization during the study. Female subjects who are pregnant or lactating, or female subjects of child bearing potential who are not using acceptable methods of birth control. Acceptable methods of birth control include: barrier (diaphragm or condom) with spermicide intrauterine progesterone contraceptive system levonorgestrel implant medroxyprogesterone acetate contraceptive injection oral contraceptives. Patients with impaired renal function as indicated by corrected creatinine clearance below 80 ml/min/70 kg as determined by the modified Cockcroft equation (CDC, 1986). Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits that are clinically unacceptable to the Principal Investigator. EKG 1st degree heart block, sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes are allowed; liver function tests [LFTs] <5 x ULN are acceptable). A complete list of exclusionary lab results are included in the appendix 1

Sites / Locations

  • University of Pennsylvania

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Propranolol

Amantadine

Propranolol and Amantadine

Placebo

Arm Description

Propranolol 100mg/day in 3 divided doses

Amantadine 100mg three times daily

Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily

Identical Placebo pills

Outcomes

Primary Outcome Measures

Cocaine abstinence; measured by self-reported Time line follow-back and confirmed with cocaine urine tests.

Secondary Outcome Measures

Full Information

First Posted
September 8, 2005
Last Updated
January 11, 2017
Sponsor
University of Pennsylvania
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00158132
Brief Title
Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2
Official Title
A Double-Blind, Placebo Controlled Trial of Propranolol and Amantadine for the Treatment of Cocaine Dependent Subjects With Severe Cocaine Withdrawal Symptoms
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
September 1999 (undefined)
Primary Completion Date
March 2005 (Actual)
Study Completion Date
February 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Pennsylvania
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Amantadine, a medication that improves muscle control, and propranolol, a medication that lowers blood pressure, may be useful in treating cocaine addiction in individuals with severe cocaine withdrawal symptoms. This study will evaluate the effectiveness of amantadine and propranolol in preventing drug relapse among cocaine addicts.
Detailed Description
Cocaine withdrawal symptoms are a major contributing factor for why outpatient cocaine dependence treatment programs often fail. Individuals with severe cocaine withdrawal symptoms often experience anxiety, shaking, and muscle pain. Amantadine is a medication currently used to improve muscle control, reduce shaking, and lessen stiffness. Therefore, it may help reduce the muscle pain that some cocaine addicts experience. By enhancing activity of the brain chemical dopamine, amantadine may also reduce other symptoms associated with cocaine withdrawal. Propranolol is a medication currently used to treat high blood pressure and irregular heart rhythms. It may reduce anxiety and lessen cocaine cravings in individuals addicted to cocaine. The purpose of this study is to evaluate the effectiveness of amantadine and propranolol, alone and in combination, for treating cocaine addicts with severe cocaine withdrawal symptoms. A 2-week baseline evaluation period will be followed by an 8-week treatment phase. During the baseline evaluation, cocaine use will be measured with urine tests, three times each week. Only participants who are experiencing severe withdrawal symptoms and who use cocaine at least twice during the first 2 weeks will continue in the study. Eligible individuals will then be randomly assigned to receive amantadine alone, propranolol alone, a combination of amantadine and propranolol, or placebo. Treatments will begin at Week 3 and study visits will occur three times each week. Cocaine levels will be monitored throughout the study with urine tests.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders
Keywords
cocaine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
199 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Propranolol
Arm Type
Experimental
Arm Description
Propranolol 100mg/day in 3 divided doses
Arm Title
Amantadine
Arm Type
Experimental
Arm Description
Amantadine 100mg three times daily
Arm Title
Propranolol and Amantadine
Arm Type
Experimental
Arm Description
Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Identical Placebo pills
Intervention Type
Drug
Intervention Name(s)
Propranolol
Intervention Description
Propranolol 100mg/day in 3 divided doses
Intervention Type
Drug
Intervention Name(s)
Amantadine
Intervention Description
Amantadine 100mg three times daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo pills
Primary Outcome Measure Information:
Title
Cocaine abstinence; measured by self-reported Time line follow-back and confirmed with cocaine urine tests.
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and females, 18 to 60 years old. Meets DSM-IV diagnosis criteria for cocaine dependence as determined by the Structured Clinical Interview for DSM-IV (SCID) Score of at least (> or =) 22 on the Initial Cocaine Selective Severity Assessment (CSSA) Lives within commuting distance of the Treatment Research Center (TRC) and the Penn/VA Center for Studies of Addiction, University of Pennsylvania If female, willing to use contraception throughout the study Continued use of cocaine during a two week evaluation phase prior to medication treatment as demonstrated by at least 2 new uses of cocaine documented by quantitative urine toxicology screen obtained three times weekly according to new use rules Exclusion Criteria: Meets DSM-IV/SCID diagnosis criteria for dependence on any drugs other than cocaine, marijuana, or nicotine. Cocaine dependent subjects who identify cocaine dependence as their primary addiction but who also meet criteria for alcohol dependence will be accepted as long as the alcohol dependence is not severe enough to require medications for alcohol detoxification. Concomitant treatment with psychotropic medications. Patients mandated to treatment based upon a legal decision or as a condition of employment. This will be assessed by the patient's self-report. Current severe psychiatric symptoms (e.g., psychosis, dementia, suicidal or homicidal ideation, mania or depression requiring antidepressant medication) Sensitivity to propranolol or amantadine Use of any investigational medication within the past 30 days. History of significant heart disease (an arrhythmia which required medication, Wolff-Parkinson -White Syndrome, angina pectoris, documented history of myocardial infarction, heart failure). History of chest pain associated with cocaine use which has prompted a visit to a physician. Current use of reserpine, verapamil, theophylline, trimethoprim, cimetidine, haloperidol, benzodiazepines, or anticonvulsants Bronchospastic disease Hyperthyroidism Diabetes mellitus Patients with known AIDS or other serious illnesses which may require hospitalization during the study. Female subjects who are pregnant or lactating, or female subjects of child bearing potential who are not using acceptable methods of birth control. Acceptable methods of birth control include: barrier (diaphragm or condom) with spermicide intrauterine progesterone contraceptive system levonorgestrel implant medroxyprogesterone acetate contraceptive injection oral contraceptives. Patients with impaired renal function as indicated by corrected creatinine clearance below 80 ml/min/70 kg as determined by the modified Cockcroft equation (CDC, 1986). Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits that are clinically unacceptable to the Principal Investigator. EKG 1st degree heart block, sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes are allowed; liver function tests [LFTs] <5 x ULN are acceptable). A complete list of exclusionary lab results are included in the appendix 1
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helen M. Pettinati, Ph.D.
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104 6178
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
16697124
Citation
Kampman KM, Dackis C, Lynch KG, Pettinati H, Tirado C, Gariti P, Sparkman T, Atzram M, O'Brien CP. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend. 2006 Nov 8;85(2):129-37. doi: 10.1016/j.drugalcdep.2006.04.002. Epub 2006 May 11.
Results Reference
result
Links:
URL
http://www.med.upenn.edu/csa/index.html
Description
Related Info

Learn more about this trial

Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2

We'll reach out to this number within 24 hrs